RMC No. 66-2022 updates the FDA-endorsed VAT-exempt list for certain COVID-19 treatment medical devices under the CREATE Act.

Businesses selling, importing, purchasing, or claiming VAT treatment on COVID-19-related medical devices must immediately check whether their products remain covered by the updated VAT-exempt list endorsed by the Food and Drug Administration. RMC No. 66-2022 matters because the VAT exemption under Republic Act No. 11534, or the CREATE Act, depends on whether the medical device appears in the proper FDA-endorsed list, as updated, deleted, or corrected. A product that was previously treated as VAT-exempt may no longer be treated the same way if it was deleted or corrected, while a newly included medical device may now require different invoice, accounting, and tax return treatment.

What Changed Under RMC No. 66-2022

RMC No. 66-2022 publishes the full text of the April 8, 2022 letter from Food and Drug Administration OIC-Director General Oscar G. Gutierrez, Jr. endorsing updates to the List of Medical Devices Exempt from VAT under Republic Act No. 11534, otherwise known as the CREATE Act.

The core change is not a new VAT rate, but an update to the coverage of medical devices that may be treated as VAT-exempt. The FDA-endorsed list includes, deletes, and corrects certain medical devices for COVID-19 treatment. This means taxpayers cannot rely on an older list, internal product classification, supplier representation, or generic descriptions such as medical supplies or COVID-19 devices. The controlling question for compliance is whether the relevant medical device is included in the updated FDA-endorsed VAT-exempt list as published through RMC No. 66-2022.

For Philippine tax compliance purposes, the important search terms are RMC 66-2022 VAT exempt medical devices, CREATE Act medical devices VAT exemption, FDA list VAT exempt COVID-19 devices, BIR VAT exemption medical devices Philippines, and COVID-19 treatment devices VAT exemption. These are the practical phrases that accountants and tax managers should use when reviewing past and current VAT treatment.

Who Is Affected

The most directly affected taxpayers are importers, distributors, retailers, hospitals, clinics, pharmacies, medical suppliers, procurement teams, and companies purchasing medical devices for COVID-19 treatment. Businesses that issue VAT invoices or receipts for medical devices must pay special attention because the VAT treatment affects pricing, invoicing, output VAT reporting, and the customer’s accounting treatment.

The update is also important for corporate accountants and CFOs of healthcare companies, logistics companies handling medical-device importation, and businesses that purchased medical devices during the relevant period. If a product is newly included, deleted, or corrected in the list, the business should review whether its VAT treatment, tax coding, and supporting documentation are consistent with the updated classification.

In-house counsel and tax practitioners should also treat RMC No. 66-2022 as a compliance trigger. Contracts, purchase orders, supplier certifications, tax clauses, and pricing assumptions may have been drafted based on whether the device was considered VAT-exempt. If the list changed, the legal and commercial allocation of VAT risk may also need review.

Key Compliance Requirement: Verify the Product Against the Updated FDA-Endorsed List

The practical requirement under RMC No. 66-2022 is product-level verification. Taxpayers should identify each medical device being sold, imported, distributed, or purchased for COVID-19 treatment and confirm whether it is included, deleted, or corrected in the updated FDA-endorsed list of medical devices exempt from VAT under the CREATE Act.

This is especially important because the update expressly covers inclusions, deletions, and corrections. Inclusion means a product may qualify for VAT-exempt treatment if it falls within the FDA-endorsed list. Deletion means prior treatment should not be assumed to continue. Correction means descriptions, classifications, or product references may have changed, and taxpayers should not rely on outdated wording.

Accounting teams should update tax codes in enterprise resource planning systems, point-of-sale systems, importation files, and billing templates. A medical device tagged as VAT-exempt must be supported by the updated list and appropriate documentation. Where the product is not covered, the business should avoid treating the sale or importation as exempt solely because the device is used in healthcare or COVID-19 response.

Effective Date and Timeline

RMC No. 66-2022 was issued on May 2, 2022. The FDA endorsement letter published by the circular is dated April 8, 2022. The document does not state a separate extended transition period or grace period. For compliance planning, taxpayers should treat the issuance date of May 2, 2022 as the key BIR publication date for purposes of reviewing VAT treatment based on the updated FDA-endorsed list.

Businesses should therefore review transactions involving affected medical devices beginning from the period covered by their current or open VAT filings, especially if they relied on an older classification or list. Where the VAT treatment is uncertain, the safer approach is to retain the product documentation, FDA reference, invoice trail, and internal tax review notes supporting the position taken.

Penalties and Tax Exposure for Wrong VAT Treatment

RMC No. 66-2022 does not create a separate penalty schedule for non-compliance. However, the risk arises from incorrect VAT classification. If a business treats a taxable product as VAT-exempt without basis in the updated FDA-endorsed list, the issue may affect output VAT reporting, invoice compliance, and tax return accuracy. Conversely, if a qualifying device is incorrectly treated as VATable, pricing and customer tax treatment may be affected.

The most practical exposure is audit risk. During a BIR examination, the taxpayer may be asked to justify why a medical device was treated as VAT-exempt under the CREATE Act. A general claim that the item is a medical device may not be enough. The taxpayer should be ready to connect the specific product to the updated FDA-endorsed list published under RMC No. 66-2022.

Practical Steps for Businesses

First, identify all COVID-19 treatment medical devices sold, imported, purchased, or distributed by the company. Second, match each product against the updated FDA-endorsed VAT-exempt list referenced in RMC No. 66-2022. Third, separate the products into three working categories: included, deleted, and corrected. Fourth, update the company’s VAT coding, invoicing language, and accounting treatment based on the verified classification.

Fifth, preserve the compliance trail. Businesses should keep copies of supplier documents, FDA references, product descriptions, purchase orders, import entries, sales invoices, and internal tax memoranda showing why the product was treated as VAT-exempt or VATable. This documentation is critical because the update involves specific medical devices, not a blanket exemption for all healthcare products.

Finally, companies should review pricing and contracts. If the product’s VAT treatment changed because of inclusion, deletion, or correction, the economic burden of VAT may affect margins, customer billings, and supplier arrangements. Tax teams should coordinate with legal, procurement, sales, and finance before changing product-level VAT treatment.

How Ablola, Saribong & Gueco Can Help

RMC No. 66-2022 is a targeted but commercially important issuance for businesses dealing with VAT-exempt medical devices, COVID-19 treatment devices, healthcare procurement, and CREATE Act tax incentives. The main compliance challenge is not merely knowing that an exemption exists, but proving that the specific device falls within the updated FDA-endorsed list.

Ablola, Saribong & Gueco assists businesses, CFOs, accountants, importers, healthcare suppliers, and in-house legal teams in reviewing BIR issuances, validating VAT treatment, preparing tax compliance documentation, and responding to BIR audit concerns. For assistance with RMC No. 66-2022, VAT-exempt medical devices, or CREATE Act tax compliance, visit MakatiLawFirm.com.

Leave a Comment

Your email address will not be published. Required fields are marked *